Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial.

Blood - 12 Jan 2023

de Botton Stéphane, Montesinos Pau, Schuh Andre C, Papayannidis Cristina, Vyas Paresh, Wei Andrew H, Ommen Hans, Semochkin Sergey, Kim Hee-Je, Larson Richard A, Koprivnikar Jaime, Frankfurt Olga, Thol Felicitas, Chromik Jörg, Byrne Jenny, Pigneux Arnaud, Thomas Xavier, Salamero Olga, Vidriales Maria Belen, Doronin Vadim, Döhner Hartmut, Fathi Amir T, Laille Eric, Yu Xin, Hasan Maroof, Martin-Regueira Patricia, DiNardo Courtney D

Abstract excerpt

This open-label, randomized, phase 3 trial (NCT02577406) compared enasidenib, an oral IDH2 (isocitrate dehydrogenase 2) inhibitor, with conventional care regimens (CCRs) in patients aged ≥60 years with late-stage, mutant-IDH2 acute myeloid leukemia (AML) relapsed/refractory (R/R) to 2 or 3 prior AML-directed therapies. Patients were first preselected to a CCR (azacitidine, intermediate-dose cytarabine, low-dose...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytarabine

Share to Isocitrate Dehydrogenase

Share to Leukemia, Myeloid, Acute

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 35714312
DOI: 10.1182/blood.2021014901
PMCID: PMC10644040

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial.PMID 35714312Read ↗

Real-world clinical outcomes with enasidenib in relapsed or refractory acute myeloid leukemia.Semantic proximity Read ↗

Long-term remission and survival in older adults with IDH-mutated acute myeloid leukemia treated with IDH inhibitors.Semantic proximity Read ↗

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.Semantic proximity Read ↗

Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial.Semantic proximity Read ↗

A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML.Semantic proximity Read ↗

Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy.Semantic proximity Read ↗

Cost-effectiveness of Enasidenib versus conventional care for older patients with IDH2-mutant refractory/relapsed AML.Semantic proximity Read ↗

Enasidenib for relapsed/refractory acute myeloid leukemia with IDH2 mutations: optimizing the patient experience.Semantic proximity Read ↗

Enasidenib for the treatment of acute myeloid leukemia.Semantic proximity Read ↗

Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysis.Semantic proximity Read ↗

Enasidenib: First Global Approval.Semantic proximity Read ↗

Enasidenib, a targeted inhibitor of mutant IDH2 proteins for treatment of relapsed or refractory acute myeloid leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.